About the Company
BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NTGN News
GSK Sues Pfizer, BioNTech for Share of Billions in Vaccine Sales
GlaxoSmithKline filed a federal lawsuit seeking to recoup a share of the tens of billions of dollars in revenue Pfizer and ...
What's Going On With Pfizer Stock On Thursday?
GSK Plc (NYSE:GSK) has reportedly taken legal action against Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a ...
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster ...
Pfizer wins pause on Moderna's COVID-19 patent lawsuit
Moderna's patent lawsuit claiming Pfizer and BioNTech copied its COVID-19 vaccine technology will be put on hold while the ...
Pfizer and BioNTech commence legal action against Moderna in UK court
Pfizer and its Germany partner BioNTech have urged London’s High Court to invalidate competitor Moderna's patents over ...
25 Richest Billionaires in Healthcare Industry
In this article, we discuss the 25 richest billionaires in healthcare industry. To skip the detailed analysis of the ...
Walgreens Loses Bid to Nix Worker Class Suit Over Credit Check
Walgreens Boots Alliance Inc. failed to shake a proposed class lawsuit by a worker who says she was fired on her second day ...
Reuters Health News Summary
Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but lowered its earnings outlook to include the ...
Medigene AG reports Financial Results and Business Update for Q1 2024
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today ...
Baron Focused Growth Fund Q1 2024 Shareholder Letter
Baron Focused Growth Fund increased 1.68% in the first quarter. The Fund underperformed the Russell 2500 Growth Index (the ...
GlaxoSmithKline sues Pfizer, BioNTech over Covid-19 vaccine technology
GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of COVID-19 ...
Loading the latest forecasts...